PE20040640A1 - Compuestos de tiazol como inhibidores de la enzima gamma secretasa - Google Patents
Compuestos de tiazol como inhibidores de la enzima gamma secretasaInfo
- Publication number
- PE20040640A1 PE20040640A1 PE2003001021A PE2003001021A PE20040640A1 PE 20040640 A1 PE20040640 A1 PE 20040640A1 PE 2003001021 A PE2003001021 A PE 2003001021A PE 2003001021 A PE2003001021 A PE 2003001021A PE 20040640 A1 PE20040640 A1 PE 20040640A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- phenyl
- thiazol
- difluoro
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
SE REFIERE A UN COMPUESTOS DE TIAZOL DE FORMULA (I), DONDE A ES -C(=O)C(=O)-, -C(=O)NR9-, -C(=O)Z-, -C(=S)Z-, ENTRE OTROS; Z ES -CH2-, -CH(OH)-, -CH(OC(=O)R11)-, ENTRE OTROS; R1 ES ALQUILO(C1-C20), ALCOXI(C1-C20), CICLOALQUILO(C3-C8), CICLOALQUENILO(C4-C8), BI O TRICICLOALQUILO(C5-C11), ENTRE OTROS; R2 ES H, ALQUILO(C1-C4), -C(=O)(ALQUILO(C1-C4)), ARILO(C6-C10), ENTRE OTROS; R3 ES ALQUILO(C1-C6), ALQUENILO(C2-C6), ALQUINILO(C2-C6), -(ALQUILENO(C0-C4))-(CICLOALQUILO(C3-C6)), ENTRE OTROS; R4 ES H, D, F, ALQUILO(C1-C4) O R3 Y R4 FORMAN UN CICLOPROPILO, CICLOBUTILO, CICLOHEXILO, MORFOLINO, ENTRE OTROS; R6 ES -H, -ALQUILO(C1-C20), HALOGENO, -CN, -CF3, -C(=O)R11, ENTRE OTROS; R7 ES H, HALOGENO, -CN, -NO2, -CF3, ALQUILO (C1-C20), ALCOXI(C1-C20), O R6 Y R7 FORMAN UN ANILLO ARILO(C6-C10), CICLOALQUILO O CICLOALQUENILO(C6-C8), HETEROCICLOALQUILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-[2-(3,5-DIFLUORO-FENIL)-ACETILAMINO]-N-(4-FENIL-TIAZOL-2-IL)-PROPIONAMIDA, ESTER ETILICO DEL ACIDO 2-{2-[2-(3,5-DIFLUORO-FENIL)-ACETILAMINO]-PROPIONILAMINO}-4-FENIL-TIAZOL-5-CARBOXILICO, [5-(1-BUTILAMINO-ETIL)-4-METIL-TIAZOL-2-IL]-AMIDA DEL ACIDO 2-[2-(3,5-DIFLUORO-FENIL)-ACETAMINO]-PENTANOICO, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE LO CONTIENE. ESTOS COMPUESTOS INHIBEN LA PRODUCCION DE Aß-PEPTIDOS DEBIDO A SU ACTIVIDAD INHIBITORIA DE LA ENZIMA GAMMA-SECRETASA Y SON UTILES PARA EL TRATAMIENTO DE TRANSTORNOS NEURODEGENERATIVOS COMO EL MAL DE ALZHEIMER
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41740002P | 2002-10-09 | 2002-10-09 | |
US46320903A | 2003-06-17 | 2003-06-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20040640A1 true PE20040640A1 (es) | 2004-09-15 |
Family
ID=35306299
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2003001021A PE20040640A1 (es) | 2002-10-09 | 2003-10-07 | Compuestos de tiazol como inhibidores de la enzima gamma secretasa |
Country Status (28)
Country | Link |
---|---|
US (1) | US20040152747A1 (es) |
EP (1) | EP1551815A1 (es) |
JP (1) | JP2006504796A (es) |
KR (1) | KR20050070046A (es) |
CN (1) | CN1688557A (es) |
AP (1) | AP2005003274A0 (es) |
AR (1) | AR043051A1 (es) |
AU (1) | AU2003265068A1 (es) |
BR (1) | BR0314611A (es) |
CA (1) | CA2501803A1 (es) |
CO (1) | CO5550435A2 (es) |
CR (1) | CR7785A (es) |
EC (1) | ECSP055719A (es) |
GT (1) | GT200300219A (es) |
IS (1) | IS7738A (es) |
MA (1) | MA27451A1 (es) |
MX (1) | MXPA05002420A (es) |
NL (1) | NL1024499C2 (es) |
NO (1) | NO20052223L (es) |
OA (1) | OA12937A (es) |
PA (1) | PA8585001A1 (es) |
PE (1) | PE20040640A1 (es) |
PL (1) | PL376171A1 (es) |
TN (1) | TNSN05104A1 (es) |
TW (1) | TW200420550A (es) |
UY (1) | UY28011A1 (es) |
WO (1) | WO2004033439A1 (es) |
ZA (1) | ZA200502841B (es) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2842523A1 (fr) * | 2002-07-17 | 2004-01-23 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur application en therapeutique |
BRPI0409721A (pt) * | 2003-05-12 | 2006-05-02 | Pfizer Prod Inc | compostos de isoxazol e isotiazol para o tratamento de distúrbios neurodegenerativos |
EP1653952A4 (en) * | 2003-08-06 | 2007-04-04 | Pfizer Prod Inc | OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDER |
FR2865206B1 (fr) * | 2004-01-16 | 2009-02-06 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur application en therapeutique |
JP2007517840A (ja) * | 2004-01-16 | 2007-07-05 | サノフイ−アベンテイス | アシルアミノチアゾール誘導体、それらの調製方法及び治療における該誘導体の使用 |
FR2873374B1 (fr) * | 2004-07-22 | 2006-10-20 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur application en therapeutique |
FR2873370B1 (fr) * | 2004-07-22 | 2006-10-20 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur application en therapeutique |
JP4813371B2 (ja) | 2004-01-16 | 2011-11-09 | サノフイ−アベンテイス | アシルアミノチアゾール誘導体及びβ−アミロイド阻害剤としてのこれらの使用 |
FR2865207B1 (fr) * | 2004-01-16 | 2008-10-17 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur application en therapeutique |
RS50595B (sr) * | 2004-03-23 | 2010-05-07 | Pfizer Products Incorporated | Jedinjenja imidazola za lečenje neurodegenerativnih poremećaja |
US7220865B2 (en) * | 2004-04-01 | 2007-05-22 | Pfizer Inc | Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders |
US7384968B2 (en) | 2004-04-01 | 2008-06-10 | Pfizer Inc. | Thiazole-amine compounds for the treatment of neurodegenerative disorders |
AU2005272815A1 (en) | 2004-08-13 | 2006-02-23 | Genentech, Inc. | Thiazole based inhibitors of ATP-utilizing enzymes |
BRPI0611029A2 (pt) * | 2005-05-24 | 2010-08-10 | Serono Lab | derivados de tiazol e uso dos mesmos |
FR2887879B1 (fr) * | 2005-07-01 | 2008-09-26 | Trophos Sa | Nouveaux composes chimiques et leurs utilisations comme medicament,particulierement dans le traitement des maladies neurodegeneratives |
EP1940802A2 (en) * | 2005-09-22 | 2008-07-09 | Pfizer Products Inc. | Imidazole compounds for the treatment of neurological disorders |
EP1968597A4 (en) * | 2005-12-01 | 2012-01-11 | Scripps Research Inst | COMPOSITIONS AND METHODS FOR INDUCING NEURONAL DIFFERENTIATION |
CA2636077C (en) * | 2006-01-18 | 2012-01-03 | Amgen Inc. | Thiazole compounds as protein kinase b (pkb) inhibitors |
EP1918286B1 (en) * | 2006-11-05 | 2011-12-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Thiazolhydrazides for treatment of neurodegenerative diseases |
GB0701426D0 (en) * | 2007-01-25 | 2007-03-07 | Univ Sheffield | Compounds and their use |
CA2692713A1 (en) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Heterocyclic modulators of pkb |
WO2009011871A2 (en) * | 2007-07-17 | 2009-01-22 | Amgen Inc. | Thiadiazole modulators of pkb |
US8703761B2 (en) | 2008-07-15 | 2014-04-22 | Novartis Ag | Organic compounds |
JP5705748B2 (ja) | 2009-02-18 | 2015-04-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を変調する複素環化合物 |
WO2010126002A1 (ja) * | 2009-04-28 | 2010-11-04 | 塩野義製薬株式会社 | ヘテロ環スルホンアミド化合物を含有する医薬 |
US8299103B2 (en) * | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
JP2013517271A (ja) | 2010-01-15 | 2013-05-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を調節する化合物 |
US8846936B2 (en) | 2010-07-22 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the CB2 receptor |
CN102351854B (zh) * | 2011-07-29 | 2014-06-04 | 华中科技大学 | 氨基噻唑衍生物及制备方法和医药用途 |
DK2970272T3 (en) * | 2013-03-14 | 2019-04-23 | Merck Patent Gmbh | glycosidase |
EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
CN103435573B (zh) * | 2013-07-16 | 2015-04-01 | 浙江医药高等专科学校 | 苄基取代的噻唑并环己烷类化合物、其制备方法和用途 |
CN103408541B (zh) * | 2013-07-16 | 2015-04-01 | 浙江医药高等专科学校 | 吲哚取代的噻唑并环己烷类化合物、及其抗肿瘤用途 |
GB201401886D0 (en) * | 2014-02-04 | 2014-03-19 | Lytix Biopharma As | Neurodegenerative therapies |
WO2018235966A1 (ja) * | 2017-06-21 | 2018-12-27 | 第一三共株式会社 | Ep300/crebbp阻害剤 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992021360A1 (en) * | 1991-05-28 | 1992-12-10 | Merck & Co., Inc. | Substituted n-carboxyalkylpeptidyl derivatives as antidegenerative active agents |
CO5021134A1 (es) * | 1998-05-01 | 2001-03-27 | Abbott Lab | Inhibidores beta-aminoacidos substituidos de aminopeptida- sa-2 metionina |
WO1999057098A2 (en) * | 1998-05-01 | 1999-11-11 | Abbott Laboratories | Substituted beta-amino acid inhibitors of methionine aminopeptidase-2 |
WO2000024392A1 (fr) * | 1998-10-26 | 2000-05-04 | Sumitomo Pharmaceuticals Company, Limited | Inhibiteur de la formation de beta-amyloide |
AR039059A1 (es) * | 2001-08-06 | 2005-02-09 | Sanofi Aventis | Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios |
FR2842523A1 (fr) * | 2002-07-17 | 2004-01-23 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur application en therapeutique |
-
2003
- 2003-09-29 CN CNA038240106A patent/CN1688557A/zh active Pending
- 2003-09-29 CA CA002501803A patent/CA2501803A1/en not_active Abandoned
- 2003-09-29 EP EP03807933A patent/EP1551815A1/en not_active Withdrawn
- 2003-09-29 BR BR0314611-1A patent/BR0314611A/pt not_active IP Right Cessation
- 2003-09-29 KR KR1020057006168A patent/KR20050070046A/ko not_active Application Discontinuation
- 2003-09-29 MX MXPA05002420A patent/MXPA05002420A/es not_active Application Discontinuation
- 2003-09-29 AP AP2005003274A patent/AP2005003274A0/xx unknown
- 2003-09-29 WO PCT/IB2003/004330 patent/WO2004033439A1/en active Application Filing
- 2003-09-29 AU AU2003265068A patent/AU2003265068A1/en not_active Abandoned
- 2003-09-29 OA OA1200500098A patent/OA12937A/en unknown
- 2003-09-29 PL PL03376171A patent/PL376171A1/xx not_active Application Discontinuation
- 2003-09-29 JP JP2005501002A patent/JP2006504796A/ja active Pending
- 2003-10-03 TW TW092127495A patent/TW200420550A/zh unknown
- 2003-10-07 PE PE2003001021A patent/PE20040640A1/es not_active Application Discontinuation
- 2003-10-08 US US10/682,686 patent/US20040152747A1/en not_active Abandoned
- 2003-10-08 AR ARP030103662A patent/AR043051A1/es unknown
- 2003-10-08 PA PA20038585001A patent/PA8585001A1/es unknown
- 2003-10-09 UY UY28011A patent/UY28011A1/es not_active Application Discontinuation
- 2003-10-09 NL NL1024499A patent/NL1024499C2/nl not_active IP Right Cessation
- 2003-10-09 GT GT200300219A patent/GT200300219A/es unknown
-
2005
- 2005-03-10 IS IS7738A patent/IS7738A/is unknown
- 2005-04-07 EC EC2005005719A patent/ECSP055719A/es unknown
- 2005-04-07 CR CR7785A patent/CR7785A/es not_active Application Discontinuation
- 2005-04-08 MA MA28206A patent/MA27451A1/fr unknown
- 2005-04-08 CO CO05031337A patent/CO5550435A2/es not_active Application Discontinuation
- 2005-04-08 TN TNP2005000104A patent/TNSN05104A1/fr unknown
- 2005-05-06 NO NO20052223A patent/NO20052223L/no unknown
-
2006
- 2006-01-17 ZA ZA200502841A patent/ZA200502841B/en unknown
Also Published As
Publication number | Publication date |
---|---|
PL376171A1 (en) | 2005-12-27 |
CR7785A (es) | 2005-07-08 |
MA27451A1 (fr) | 2005-07-01 |
NO20052223L (no) | 2005-07-04 |
ECSP055719A (es) | 2005-07-06 |
BR0314611A (pt) | 2005-07-26 |
AU2003265068A1 (en) | 2004-05-04 |
JP2006504796A (ja) | 2006-02-09 |
TNSN05104A1 (fr) | 2007-05-14 |
CN1688557A (zh) | 2005-10-26 |
AR043051A1 (es) | 2005-07-13 |
WO2004033439A1 (en) | 2004-04-22 |
EP1551815A1 (en) | 2005-07-13 |
NL1024499A1 (nl) | 2004-04-13 |
TW200420550A (en) | 2004-10-16 |
NL1024499C2 (nl) | 2004-10-13 |
GT200300219A (es) | 2004-05-18 |
MXPA05002420A (es) | 2005-10-05 |
IS7738A (is) | 2005-03-10 |
AP2005003274A0 (en) | 2005-06-30 |
PA8585001A1 (es) | 2004-12-16 |
CA2501803A1 (en) | 2004-04-22 |
OA12937A (en) | 2006-10-13 |
KR20050070046A (ko) | 2005-07-05 |
UY28011A1 (es) | 2004-04-30 |
ZA200502841B (en) | 2006-03-29 |
CO5550435A2 (es) | 2005-08-31 |
NO20052223D0 (no) | 2005-05-06 |
US20040152747A1 (en) | 2004-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20040640A1 (es) | Compuestos de tiazol como inhibidores de la enzima gamma secretasa | |
PE20051155A1 (es) | Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos | |
CO5700824A2 (es) | Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen | |
PE20090041A1 (es) | Derivados de triazol como inhibidores de la biosintesis de leucotrienos | |
PE20041016A1 (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
MX2011008305A (es) | Compuestos de piridazinona. | |
PE20061123A1 (es) | Derivados de amida como inhibidores de la hidrolasa de amida de acido graso | |
KR20080098443A (ko) | 세라마이드 키나제 조절 | |
PE20061303A1 (es) | Composicion farmaceutica que comprende oxaprozina | |
BRPI0417110A (pt) | inibidores de fosfodiesterase 4, incluindo análogos de diarilamina n-substituìdos, composto, composição farmacêutica, método para aumentar a cognição em um paciente no qual tal aumento é desejado, método de tratamento de um paciente que sofre de degeneração ou declìnio da cognição, método para o tratamento de um paciente que tem uma doença que envolve nìveis reduzidos de camp, método de inibição da atividade da enzima pde4 em uma paciente, método de tratamento de um paciente que sofre de degeneração da memória devido a uma doença neurodegenerativa, método de tratamento de um paciente que sofre de degeneração da memória devida a um distúrbio neurodegenerativo agudo, método de tratamento de um paciente que sofre de uma doença alérgica ou inflamatória, método para o tratamento de um paciente que sofre de esquizofrenia, método para o tratamento de um paciente que sofre de psicose caracterizada por nìveis elevados pde4, sendo que a dita psicose é uma forma de depressão | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
MA30456B1 (fr) | Nouveau dérivé de coumarine présentant une activité anti-tumorale. | |
CA2581865A1 (en) | Indazolone derivatives as 11b-hsd1 inhibitors | |
MA32965B1 (fr) | Derives de sulfonamides | |
PE20081897A1 (es) | 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas | |
AR047671A1 (es) | Compuestos de arilnitrona 2-sustituidos y 4-sustituidos | |
WO2005012269A8 (ja) | 新規アゾール化合物 | |
AR059895A1 (es) | Derivados biciclicos de acidos carboxilicos que resultan de utilidad para tratar trastornos metabolicos | |
NZ602099A (en) | Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient | |
PE20090773A1 (es) | Derivados de morfolina pirimidina | |
PE20070359A1 (es) | Inhibidores de pirimidinilpirazol de aurora quinasas | |
MX2010000658A (es) | Derivados de pirimidina 934. | |
JP2008524175A (ja) | cdc25ホスファターゼ阻害剤 | |
PE20110420A1 (es) | Nuevos derivados de 2-amidotiadiazol | |
PE20091102A1 (es) | Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |